139 related articles for article (PubMed ID: 37403534)
1. Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.
Matsuura Y; Mun M; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
J Surg Oncol; 2023 Oct; 128(5):916-924. PubMed ID: 37403534
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
Matsuura Y; Ninomiya H; Ichinose J; Nakao M; Okumura S; Nishio M; Mun M
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):441-451.e1. PubMed ID: 33131892
[TBL] [Abstract][Full Text] [Related]
3. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma.
Zhang H; Shan G; Cai B; Bi G; Chen Z; Liang J; Besskaya V; Zheng Y; Guo W; Wang L; Xu S; Zhan C
Thorac Cancer; 2021 Nov; 12(22):3011-3018. PubMed ID: 34596344
[TBL] [Abstract][Full Text] [Related]
6. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
10. Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival.
Fujibayashi Y; Tane S; Kitazume M; Kuroda S; Kimura K; Kitamura Y; Nishio W
Thorac Cancer; 2022 Apr; 13(8):1109-1116. PubMed ID: 35274461
[TBL] [Abstract][Full Text] [Related]
11. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
13. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
[TBL] [Abstract][Full Text] [Related]
15. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
17. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
18. Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India.
Mohapatra PR; Sahoo S; Bhuniya S; Panigrahi MK; Majumdar SKD; Mishra P; Patra S
J Cancer Res Ther; 2020; 16(4):850-854. PubMed ID: 32930129
[TBL] [Abstract][Full Text] [Related]
19. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
20. Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients.
Song L; Zhu Z; Wu H; Han W; Cheng X; Li J; Du H; Lei J; Sui X; Song W; Jin ZY
Eur Radiol; 2021 Apr; 31(4):2034-2047. PubMed ID: 33146791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]